Area of study
Year of enrolment
Why did you choose Hudson Institute and your research group?
It wasn't a hard decision to make to join the Jenkins group in a well-regarded institution, Hudson Institute. The area of research in the Jenkins group matches my interest. The high research standards in the Jenkins group is attractive to any researcher, being a member of such a successful group is having a major influence on my success in research. As it's said, all you need to succeed is to be surrounded by successful people.
What is your research about and what do you hope to achieve?
The aim of my research is to explore the role of STAT3 serine phosphorylation in the molecular pathogenesis of Lung Adenocarcinoma, and to formally prove that the mitochondrial form of STAT3 can be targeted therapeutically to ameliorate Kras-associated tumourigenesis in mouse disease models whilst sparing the required nuclear activities of STAT3 in normal tissues using a combination of genetic and therapeutic approaches.
What is it like being a student at Hudson Institute?
Student life at Hudson Institute is unique and inspiring. You need to work hard to get lost in here. Everybody is helpful and supportive, if you get stuck, you just need to look around and you will see someone welling to help. I enjoy learning new advanced techniques everyday in a great research environment, Hudson Institute.
What opportunities have you had at Hudson Institute?
Through the last two and have years, I have been lucky to generate data that have led to owning me a co-authorship in publications in Cancer Research, Oncogene and American Journal of Respiratory and Critical Care Medicine journals.
I also participated in the largest lung biology conference in Australia; Thoracic Society of Australia and New Zealand, Perth 2016, where I did an oral presentation to the scientific community. In addition, I received a Travel Award from the Thoracic Society of Australia and New Zealand.
How will your research help others?
Understanding the role of STAT3 serine phosphorylation in causing Lung Cancer could contribute to the treatment of lung cancer by targeting the STAT3 serine phosphorylation therapeutically. Scientific knowledge is cumulative, the better we understand the nature of cancer, the closer we come to defeating it.